Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Phase 2

Completed

• Conditions: Benign Prostatic Hyperplasia
• Interventions: Drug: Tadalafil 5 mg; Drug: Tadalafil 2.5 mg; Drug: Placebo

• Registration Number: NCT00783094
• Lead Sponsor: Eli Lilly and Company

Brief Summary

This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese men with signs and symptoms of benign prostatic hyperplasia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-10-30
• Study First Submitted QC: 2008-10-30
• Study First Posted: 2008-10-31
• Study Start: 2008-11
• Primary Completion: 2009-06
• Study Completion: 2010-04
• Results First Submitted: 2010-06-25
• Results First Submitted QC: 2010-06-25
• Results First Posted: 2010-07-28
• Status Verified: 2011-03
• Last Update Submitted: 2011-03-18
• Last Update Posted: 2011-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 422

Inclusion Criteria

• Japanese Males, 45 years old or older, with benign prostatic hyperplasia (BPH) for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.
• Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED), and/or overactive bladder (OAB) treatments at any time during the study.
• Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to Visit 2.

Read More

Exclusion Criteria

• Prostate specific antigen (PSA) score beyond acceptable range defined for study at Visit 1.
• History of urinary retention or lower urinary tract (bladder) stones within 6 months of Visit 1.
• History of urethral obstruction due to stricture, valves, sclerosis, or tumor at Visit 1.
• Clinical evidence of prostate cancer at Visit 1.
• Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at Visit 1.
• History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study.
• History of significant central nervous system (CNS) injuries (including stroke or spinal cord injury) within 6 months of Visit 1.
• Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH) agonists/antagonists, or anabolic steroids at Visit 1.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tadalafil 5 mg	Tadalafil 5 mg	5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
Tadalafil 2.5 milligrams (mg)	Tadalafil 2.5 mg	2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
Placebo	Placebo	Placebo tablet taken by mouth once a day for 12 weeks. Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint	Baseline, 12 weeks	The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint	Baseline, 12 weeks	IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint	Baseline, 12 weeks	IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint	Baseline, 12 weeks	Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint	Baseline, 12 weeks	The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint	Baseline, 12 weeks	Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement	Baseline, 12 weeks	Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.
Number of Participants With Adverse Events During 12 Weeks of the Study	Baseline through 12 weeks	A listing of Adverse Events are reported in the Reported Adverse Event Section.
Change From Baseline in Blood Pressure at 12-Week Endpoint	Baseline, 12 weeks
Change From Baseline in Sitting Heart Rate at 12-Week Endpoint	Baseline, 12 Weeks
Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint	Baseline, 12 weeks	Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.
Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint	Baseline, 12 weeks	Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint	Baseline, 54 weeks	The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint	Baseline, 54 weeks	IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint	Baseline, 54 weeks	IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint	Baseline, 54 weeks	Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint	Baseline, 54 weeks	The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint	Baseline, 54 weeks	Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment	End of 12 weeks of double-blind through 54 weeks	A listing of Adverse Events are reported in the Reported Adverse Event Section.
Change From Baseline in Blood Pressure During at 54-Week Endpoint	Baseline, 54 weeks
Change From Baseline in Sitting Heart Rate at 54-Week Endpoint	Baseline, 54-weeks
Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint	Baseline, 54 weeks	Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint	Baseline, 54 weeks	Post residual volume (PVR) is measured by ultrasound at regular intervals.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇯🇵 Tokyo, Japan